Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ENSEMBLE

- PMLiVE

Valneva launches phase 1/2 COVID-19 vaccine trials in the UK

UK government has pre-ordered 60 million doses of candidate

- PMLiVE

EU fast-tracks review of Pfizer/BioNTech COVID-19 vaccine

CHMP meeting scheduled for 21 December

- PMLiVE

FDA experts back safety and efficacy of Moderna’s COVID-19 vaccine

Briefing document published ahead of advisory committee meeting

How has the pandemic reshaped the NHS in 2020?

Oli Hudson, of Wilmington Healthcare, explores the major changes that have occurred across the NHS as key aspects of the Long Term Plan are rolled out at speed.

Wilmington Healthcare

- PMLiVE

Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants

Phase 2b study has been delayed to February 2021

- PMLiVE

FDA expert panel recommends EUA for Pfizer/BioNTech COVID-19 vaccine

Formal approval in the US could follow 'within days'

Strategies to Launch and Commercialize Healthcare Innovations

Dr. Roxie Mooney, Healthcare Commercialization Strategist at Legacy DNA and best-selling author, joins Natalie Yeadon, Co-owner & Managing Director at Impetus Digital. We are discussing all things healthcare innovation and commercialization,...

Impetus Digital

Effects of the Pandemic on Evidence Generation & Scientific Exchange

Farah Husein, Director, Evidence Generation, Canadian Centre of Excellence, at Takeda, discusses all things evidence generation, including the impact of the COVID-19 pandemic on HEOR, RWE, epidemiology, and PRO studies and...

Impetus Digital

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

- PMLiVE

UK regulator warns of allergic reactions to Pfizer/BioNTech vaccine

New MHRA guidance comes after reports of allergic reactions to COVID-19 vaccine

- PMLiVE

FDA briefing document paves the way for Pfizer/BioNTech COVID-19 vaccine approval

Advisory Committee is set to meet today to discuss vaccine's safety and efficacy data

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links